Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101842 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
A Phase 1 study of Carcinoma, Transitional Cell, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
- 1
- Study location
NCT00101842 is a Phase 1 study of Carcinoma, Transitional Cell that has completed, run by Eli Lilly and Company. The registered enrollment target is 61 participants, below the 298-participant average among 5 other Carcinoma, Transitional Cell trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00101842, a Phase 1 study of Carcinoma, Transitional Cell, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine and any side effects that might be associated with the combination of these drugs; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can help patients with advanced bladder cancer live longer; To determine whether Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine can make your tumor smaller or disappear, and for how long.
Conditions Studied
Interventions
- DRUG Pemetrexed
- DRUG Gemcitabine
- DRUG Platinol
Study Locations (1)
Texas
- For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician. - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00101842
The ClinicalTrials.gov registry entry for NCT00101842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 298-participant average among 5 other Carcinoma, Transitional Cell trials with a reported enrollment target (80% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Transitional Cell appearing as the primary indexed condition, and to 3 interventions - of which Pemetrexed is the first listed.
NCT00101842 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00101842 about?
NCT00101842 is a clinical study titled "Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer". The purposes of this study are: To determine the maximum tolerated dose of Gemcitabine and Platinol followed by Pemetrexed and Gemcitabine in patients with advanced or metastatic transitional cell carcinoma of the urothelium; To determine the safety of Gemcitabine and Platinol followed by Pemetrexed...
What is the current status of trial NCT00101842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2004-12. Estimated completion is 2006-07.
What conditions does trial NCT00101842 study?
This clinical trial studies the following conditions: Carcinoma, Transitional Cell.
What interventions are being tested in trial NCT00101842?
The interventions under investigation include: Pemetrexed (DRUG), Gemcitabine (DRUG), Platinol (DRUG).
Who is sponsoring clinical trial NCT00101842?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00101842 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Transitional Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 1
-
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
RECRUITING
-
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RECRUITING · Phase 3
-
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
COMPLETED · Phase 3
-
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.